Today, on World COPD Day, we are excited to share the results of the HOT-HMV trial presented at ERS, which show that HMV added to HOT can reduce by 51% the likelihood of readmissions to hospital or death over one year in hypercapnic COPD patients following an acute exacerbation of COPD.1 There are new prospects for better treatment of COPD—and better lives for patients.
Non-invasive ventilation is a method of delivering air for ventilatory support through a mask, as opposed to invasive ventilation which requires delivery through an endotracheal or tracheostomy tube.
When used with a mechanical ventilator, both methods provide pressurised air to increase airflow into the lungs by opening obstructed airways. This reduces the patient’s work of breathing, and improves their alveolar ventilation.
The main advantage of non-invasive ventilation is that it avoids the added complications of invasive intubation such as risks of infection, patient discomfort and airway trauma.1 And because of its reduced incidence of mortality,2,3 non-invasive ventilation is preferred over invasive ventilation where possible.
Non-invasive ventilation in COPD
Short-term non-invasive ventilation has been effective for patients hospitalised for acute exacerbations of COPD.4 Its long-term use is also showing promising benefits for patients with hypercapnic COPD.5
ResMed’s ventilator range offers a broad range of therapy modes, making them suitable for a variety of clinical needs. And because our ventilators are light and portable, they allow your patients to live a more independent life.
